缩宫素注射液致神经精神症状分析

doi:10.19803/j.1672-8629.2021.02.15

中国药物警戒 ›› 2021, Vol. 18 ›› Issue (2): 170-173.
DOI: 10.19803/j.1672-8629.2021.02.15

缩宫素注射液致神经精神症状分析

白峻松¹, 曹建英^2,*, 李佳³

¹南方医科大学卫生管理学院,广东广州 510515;
^2*潍坊市妇幼保健院药剂科,山东潍坊 261011;
³潍坊市药品不良反应监测中心,山东潍坊 261061

收稿日期:2019-11-25 修回日期:2021-02-26 出版日期:2021-02-15 发布日期:2021-02-26
通讯作者: ^*曹建英,女,副主任药师,临床药学及药品不良反应监测。E-mail：byh93@163.com
作者简介:白峻松,男,本科,医院管理。

Neuropsychiatric Symptoms Induced by Oxytocin Injection

BAI Junsong¹, CAO Jianying^2,*, Li Jia³

¹School of Health Management, Southern Medical University, Guangzhou Guangdong 510515, China;
²Department of Pharmacy, Weifang Maternal and Child Health Hospital, Weifang Shandong 261011, China;
³Weifang Adverse Drug Reaction Monitoring Center, Weifang Shandong 261061, China

Received:2019-11-25 Revised:2021-02-26 Online:2021-02-15 Published:2021-02-26

摘要/Abstract

摘要： 目的分析缩宫素注射液致神经精神症状的用药风险,为临床合理用药提供参考。方法对2018~2019年山东省药品不良反应监测数据库及2013~2017年潍坊地区合计收到缩宫素注射液可疑药品不良反应（ADR）481例相关资料进行分析。结果监测数据和国内外文献显示,神经精神症状作为新的或（和）严重不良反应为缩宫素注射液较为突出的风险。结论加强缩宫素注射液的安全性监测及风险控制,及时完善产品说明书,促进临床安全合理用药。

关键词: 缩宫素注射液, 神经精神症状, 药品不良反应

Abstract: Objective To analyze the risk of neuropsychiatric symptoms induced by oxytocin injection. Methods A total of 481 cases of suspected ADRs caused by oxytocin injection collected by the ADR monitoring database of Shandong Province between 2018 and 2019 and by Weifang between 2013 and 2017 were analyzed. Results Monitoring data, domestic and foreign literature showed that neuropsychiatric symptoms were a new risk of serious adverse reactions induced by oxytocin injection. Conclusion The safety monitoring and risk control of oxytocin injection should be strengthened, and the product specifications should be updated quickly to promote the safe and rational use of drugs in clinical practice.

Key words: oxytocin injection, neuropsychiatric symptoms, adverse drug reaction

中图分类号:

R984R969.3

白峻松, 曹建英, 李佳. 缩宫素注射液致神经精神症状分析[J]. 中国药物警戒, 2021, 18(2): 170-173.

BAI Junsong, CAO Jianying, Li Jia. Neuropsychiatric Symptoms Induced by Oxytocin Injection[J]. Chinese Journal of Pharmacovigilance, 2021, 18(2): 170-173.

参考文献

[1] Sundin C, Mazac L, Ellis K, et al.Implementation of an oxytocin checklist to improve clinical outcomes[J]. MCN. The American Journal of Maternal Child Nursing,2018, 43(3): 1.
[2] Liang XL, Hu DM, Sun YH.Serious adverse drug reactions induced by oxytocin injection: an analysis of 84 cases[J]. Anhui Medical and Pharmaceutical Journal(安徽医药), 2016, 20(10): 1993-1995.
[3] Chen X, Zhang GB, Long LP, et al.Literature analysis of 52 cases of severe adverse drug reaction induced by oxytocin injection[J]. China Pharmaceuticals(中国药业), 2016,25(22): 13-16.
[4] Song XY, Xiao C.Domestic case analysis of adverse drug reactions to oxytocin injection[J].World Clinical Drugs(世界临床药物),2015,36(7): 476-479.
[5] Chen JY, Xu XH. A case of postpartum hypersensitivity to oxytocin in term pregnancy[J]. Zhejiang Practical Medicine(浙江实用医学), 2015, 2(20): 52,58.
[6] FDA Drugs.FDA national drug code decabeose [EB/OL]. [2019-12-01].https://www.drugfuture.com/fda-ndc/detail.aspx? ProductID=42023-130_.
[7] Yang BF, Su DF.Pharmacology (药理学) [M]. 8th ed. Beijing: People's Medical Publishing House, 2014:316.
[8] Sean C Sweetman Martindale The Complete Drug Reference (The 35th edition)(马丁代尔药物大典原著第35 版)[M]Sean C Sweetman Martindale The Complete Drug Reference (The 35th edition)(马丁代尔药物大典原著第35 版)[M]. Chemical Industry Press (Biology Medical Publishing Branch),2009:1445-1446.
[9] Chinese Pharmacopoeia Commission.Pharmacopoeia of the People's Republic of China:Part One. The 2015 edition(中华人民共和国药典:一部)[M]. Beijing: China Medical Science and Technology Press, 2015: 1512.
[10] Wang YX, Jin WH, Zong WF, et al.Studies on high molecular weight substances and allergic response of oxytocin injection[J]. Chinese Journal of Biochemical and Pharmaceuticals(中国生化药物杂志), 2015, 1(35): 85-88.
[11] Liu CL, Xia DS, Tian CH.Anaphylactic shock induced by oxytocin injection in 1 case[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2015, 12(9): 570-572.
[12] Su G, Li MM, Liu WQ, et al.Diarrhea caused by oxytocin in 1 case[J]. Chinese Journal of Modern Applied Pharmacy(中国现代应用药学), 2013, 30(11):1268-1269.
[13] Knox GE.Aggregate analysis of oxytocin incidents[J]. Alta RN, 2014,69(9):30-32.
[14] Chen JG, Lu YH, Huang Q, et al.Research advances in the preparation and quality control of oxytocin[J]. Chinese Journal of Biochemical and Pharmaceuticals(中国生化药物杂志), 2012, 33(5):698-700.
[15] Yang CY, Wang LH, Liu Y.The treatment of hypersensitivity induced by oxytocin in cesarean section[J]. Journal of Clinical Medical Literature(临床医药文献杂志),2017, 4(78):15409.
[16] Huang GH, Du HR, Gong L.Analysis on global research trends of pharmacovigilance in recent five years and its implications for China[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2018, 15(5):268-275.
[17] Huang Q, Lu YH, Shi QS, et al.HPLC determination of oxytocin injection and its related substances[J]. Chinese Journal of Pharmaceutical Analysis(药物分析杂志), 2011,31(10):1856-1861.
[18] Hou YF, Song HB, Liu HL, et al.Practice and discussion on active surveillance by China hospital pharmacovigilance system[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2019,16(4):212-214.

缩宫素注射液致神经精神症状分析

Neuropsychiatric Symptoms Induced by Oxytocin Injection

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	贾晋生, 刘红亮, 王青, 侯永芳, 李馨龄. 基于知识图谱联合ERNIE-DPCNN模型的药品不良反应自动关联性评价方法研究[J]. 中国药物警戒, 2024, 21(2): 163-166.
[2]	李应芬, 韩雷. 319例注射用脑蛋白水解物药品不良反应报告分析[J]. 中国药物警戒, 2024, 21(2): 195-198.
[3]	徐伟佳, 彭崎, 黄海渝, 张磊姣, 肖华, 吴雪. 285例新型抗肿瘤药物不良反应分析[J]. 中国药物警戒, 2024, 21(2): 199-203.
[4]	郭清华, 彭笑笑, 朱萍, 刘西霖, 杨颖华, 陈志海. 氨氯地平过量致多器官功能障碍综合征1例分析[J]. 中国药物警戒, 2024, 21(2): 204-207.
[5]	方美琳, 郑慧敏, 王存泽, 王凌, 阮君山. 注射用奥沙利铂致全身肌肉疼痛1例分析[J]. 中国药物警戒, 2024, 21(2): 208-210.
[6]	陈玉艳, 张明霞, 张涛, 张晋. 斯鲁利单抗注射液致间质性肺炎不良反应1例分析[J]. 中国药物警戒, 2024, 21(2): 213-215.
[7]	曹桂萍, 邓琳琳, 朱干红, 陆颖, 马爽, 陈玲玲, 刘丽丽. 天麻首乌片致严重肝损伤1例分析[J]. 中国药物警戒, 2024, 21(2): 216-218.
[8]	高云娟, 赵旭, 白天凯, 柏兆方, 王伽伯, 宋海波, 肖小河. 基于不良反应监测大数据的药品安全风险发现与识别策略[J]. 中国药物警戒, 2024, 21(1): 1-5.
[9]	郭龙鑫, 高云娟, 吴承钊, 龙敏娟, 祝胜凯, 宋海波, 赵旭, 肖小河. 基于不良反应监测大数据的中药药源性肝损伤风险信号新发现及易感因素初探[J]. 中国药物警戒, 2024, 21(1): 15-19.
[10]	蒋文硕, 杨莉. 694例癫痫医师药师联合门诊患者药品不良反应分析[J]. 中国药物警戒, 2024, 21(1): 102-106.
[11]	陈华炎, 江东波, 郭春连, 杨家琪, 黎雨欣, 蔡伟明. 326例奈玛特韦片/利托那韦片治疗新型冠状病毒感染安全性分析[J]. 中国药物警戒, 2024, 21(1): 107-110.
[12]	刘赛月, 吕小琴, 周耘. 疑似药品不良反应死亡病例调查及报告实施要点[J]. 中国药物警戒, 2023, 20(9): 971-974.
[13]	里筱竹, 王蔷, 逄瑜, 张轶菁. 个例药品不良反应报告管理浅析与思考[J]. 中国药物警戒, 2023, 20(9): 975-977.
[14]	逄瑜, 刘博, 吕少俐, 王涛, 邢颖, 秦星宇, 田月洁, 吴文宇. 基于国际药物警戒经验探讨收集患者报告的意义[J]. 中国药物警戒, 2023, 20(9): 978-981.
[15]	刘文东, 崔欢欢, 王晓晗, 苏娴, 王海学. 我国儿童用药临床试验期间药物警戒监管体系现状及思考[J]. 中国药物警戒, 2023, 20(9): 1002-1006.